A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Status:
Not yet recruiting
Trial end date:
2028-11-13
Target enrollment:
Participant gender:
Summary
This purpose of this study is to establish proof of concept of AG-946 in participants with
LR-MDS in Phase 2a and to compare the effect of AG-946 versus placebo and to detect a dose
response for erythroid response in participants with LR-MDS in Phase 2b.